Anesthesia in the obese patient: pharmacokinetic considerations
- PMID: 15809132
- DOI: 10.1016/j.jclinane.2004.01.009
Anesthesia in the obese patient: pharmacokinetic considerations
Abstract
The prevalence of obesity has increased 15% up to 20% and represents an important challenge for the anesthesiologist in drug-dosing management. The aim of this work is to provide an overview on physiological changes and pharmacokinetic implications of obesity for the anesthesiologist. Obesity increases both fat and lean masses; however, the percentage of fat tissue increases more than does the lean mass, affecting the apparent volume of distribution of anesthetic drugs according to their lipid solubility. Benzodiazepine loading doses should be adjusted on actual weight, and maintenance doses should be adjusted on ideal body weight. Thiopental sodium and propofol dosages are calculated on total body weight (TBW). The loading dose of lipophilic opioids is based on TBW, whereas maintenance dosages should be cautiously reduced because of the higher sensitivity of the obese patient to their depressant effects. Pharmacokinetic parameters of muscle relaxants are minimally affected by obesity, and their dosage is based on ideal rather than TBW. Inhalation anesthetics with very low lipid solubility, such as sevoflurane and desflurane, allow for quick modification of the anesthetic plan during surgery and rapid emergence at the end of surgery, hence representing very flexible anesthetic drugs for use in this patient population. Drug dosing is generally based on the volume of distribution for the loading dose and on the clearance for maintenance. In the obese patient, the volume of distribution is increased if the drug is distributed both in lean and fat tissues whereas the anesthetic drug clearance is usually normal or increased.
Similar articles
-
Perioperative pharmacology in morbid obesity.Curr Opin Anaesthesiol. 2010 Aug;23(4):485-91. doi: 10.1097/ACO.0b013e32833b0a8c. Curr Opin Anaesthesiol. 2010. PMID: 20531173 Review.
-
Drug Distribution in Obesity and following Bariatric Surgery: A Literature Review.Obes Surg. 1996 Feb;6(1):17-27. doi: 10.1381/096089296765557222. Obes Surg. 1996. PMID: 10731246
-
Effects of obesity on pharmacokinetics implications for drug therapy.Clin Pharmacokinet. 2000 Sep;39(3):215-31. doi: 10.2165/00003088-200039030-00004. Clin Pharmacokinet. 2000. PMID: 11020136 Review.
-
Obesity modestly affects inhaled anesthetic kinetics in humans.Anesth Analg. 2008 Dec;107(6):1864-70. doi: 10.1213/ane.0b013e3181888127. Anesth Analg. 2008. PMID: 19020131
-
Beta-cell function and mass in type 2 diabetes.Dan Med Bull. 2009 Aug;56(3):153-64. Dan Med Bull. 2009. PMID: 19728971
Cited by
-
Influence of body fatness on propofol requirements for loss of consciousness in target-controlled infusion: A STROBE-compliant study.Medicine (Baltimore). 2022 Sep 2;101(35):e30179. doi: 10.1097/MD.0000000000030179. Medicine (Baltimore). 2022. PMID: 36107531 Free PMC article.
-
Anesthetic challenges in the obese patient.J Anesth. 2012 Oct;26(5):758-65. doi: 10.1007/s00540-012-1408-4. Epub 2012 May 6. J Anesth. 2012. PMID: 22562644 Review.
-
Lactational state modifies alcohol pharmacokinetics in women.Alcohol Clin Exp Res. 2007 Jun;31(6):909-18. doi: 10.1111/j.1530-0277.2007.00387.x. Epub 2007 Apr 13. Alcohol Clin Exp Res. 2007. PMID: 17433009 Free PMC article.
-
Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review.Curr Med Chem. 2023;30(9):1003-1028. doi: 10.2174/0929867329666220806140204. Curr Med Chem. 2023. PMID: 35946096 Review.
-
Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents.Korean J Anesthesiol. 2017 Oct;70(5):500-510. doi: 10.4097/kjae.2017.70.5.500. Epub 2017 Sep 28. Korean J Anesthesiol. 2017. PMID: 29046769 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical